A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

Inclusion Criteria: * Patients with unresectable or metastatic solid tumors willing to provide signed informed consent. * Histopathological diagnosis and metastatic status cancer at study entry. * Must have received at least 1 prior line of systemic therapy for metastatic disease but no more than 3 prior lines of treatment for metastatic disease. * Life expectancy of more than 6 months. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) score or less than 2. * Adequate organ and hematological function. * Measurable disease by RECIST v1.1 and iRECIST. Exclusion Criteria: * Patient has known untreated or symptomatic central nervous system metastasis. * Patient is receiving systemic glucocorticoids or other immunosuppressive treatments for autoimmune disease or any other medical condition. * Patient has experienced a severe hypersensitivity reaction to another monoclonal antibody. * Patient has received treatment with any systemic anti-cancer therapies within 3 weeks prior to starting study treatment. * Patient has undergone radiotherapy ≤ 4 weeks prior to starting study treatment. * Patient has received \> 3 lines of prior systemic chemotherapy for metastatic disease